This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

PROMETRIKA Selects Medidata Solutions As Strategic Partner

As clinical trial sponsors increase their focus on reducing costs, accelerating studies and mitigating risk, contract research organizations (CROs) continue to look to Medidata Solutions (NASDAQ: MDSO) as a leading source of clinical development technology. Boston-area based CRO PROMETRIKA recently joined the Medidata Partner Program in order to increase sponsor access to its range of clinical research solutions.

  • “CROs are under growing pressure to help sponsors make critical clinical and operational gains, which means viewing their research process holistically and delivering products and services that will enable them to reach the strategic goals for every pipeline,” said Graham Bunn, vice president of partnerships, Medidata Solutions. “Our partnership with PROMETRIKA reinforces both sponsor and CRO reliance on our technologies to transform the trial process, from concept to conclusion.”

After working with Medidata Rave on nearly 20 studies, PROMETRIKA joined Medidata’s Partner Program as a Medidata Services Partner and has committed to attain Rave accreditation in order to meet growing sponsor and site demand for Medidata Rave®, the industry’s leading electronic data capture (EDC) and clinical data management (CDM) system. With a strong focus on biostatistics and data management, as well as preparing FDA submissions, PROMETRIKA manages Phase I-IV trials across a range of therapeutic categories. In addition to Medidata’s market leadership, PROMETRIKA’s decision to partner with Medidata was also driven by Rave's standards-based approach to structured data, which allows for easy conversions of Rave-centric data into datasets for statistical analysis.

  • “Medidata clearly understands the business and operational challenges faced by our customer base – new and established biotechs that are working on some of the most innovative research in the world,” said Dr. Miganush Stepanians, president and CEO of PROMETRIKA. “We chose Medidata as a partner not only for its experience and expertise across the clinical development process, but also for its ability to help us continue to provide the most leading-edge technologies to our sponsor customers.”

Connect with Medidata:

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

About PROMETRIKA, LLC

Founded in 2003 in Cambridge, Massachusetts, PROMETRIKA, LLC, is a contract research organization that offers a full range of integrated clinical research services to its pharmaceutical and biotechnology clients, including clinical trial management, clinical monitoring, data management, biostatistics, medical writing and regulatory submissions. PROMETRIKA's team has extensive expertise and experience in managing clinical trials, analyzing and interpreting medical data, and preparing new drug applications for US and European regulatory agencies in a broad range of therapeutic areas. Collectively, the PROMETRIKA team has managed more than 300 clinical trials, ranging from Phase 1 pharmacokinetic crossover trials to Phase 4 long-term multi-center studies.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs